ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Diabetes mellitus is associated with altered Alzheimer's disease pathology.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetes mellitus is associated with altered Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionDiabetes mellitus (DM) is a major risk factor for dementia, yet it remains unclear whether DM accelerates cognitive decline through amyloid beta (Aβ) or tau accumulation in Alzheimer's disease (AD).
methodsIn this study, we included 2784 participants from three independent observational cohorts: the Chinese Preclinical Alzheimer's Disease Study (CPAS), the Alzheimer's Disease Neuroimaging Initiative (ADNI), and Health and Aging Brain Study-Health Disparities (HABS-HD). We examined the associations of DM with Aβ positron emission tomography (PET), tau PET, plasma phosphorylated tau (p-tau)217, and longitudinal cognitive change. We also tested whether DM modified the associations of Aβ and plasma p-tau217 with subsequent tau accumulation and explored the association of metformin use with tau accumulation.
resultsWe found that DM was associated with lower global Aβ burden and lower tau accumulation in CPAS and ADNI, in which cognitive impairment was more common than in HABS-HD. The associations of Aβ and plasma p-tau217 with tau accumulation were weaker among individuals with DM. In addition, DM was associated with reduced propagation of tau from early to later stage Braak regions. Longitudinal analyses in ADNI indicated that individuals with DM exhibited slower tau-related cognitive decline. In exploratory analyses, metformin use among individuals with DM was associated with lower tau accumulation compared to individuals without DM. DISCUSSION: These findings suggest that DM is associated with an attenuation of amyloid- and tau-related processes, particularly in participants with cognitive impairment, and further suggest that diabetes-related mechanisms and its management may modulate the progression of AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.